JP2003516394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516394A5 JP2003516394A5 JP2001543523A JP2001543523A JP2003516394A5 JP 2003516394 A5 JP2003516394 A5 JP 2003516394A5 JP 2001543523 A JP2001543523 A JP 2001543523A JP 2001543523 A JP2001543523 A JP 2001543523A JP 2003516394 A5 JP2003516394 A5 JP 2003516394A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- celecoxib
- phase purity
- crystalline
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16985699P | 1999-12-08 | 1999-12-08 | |
| US60/169,856 | 1999-12-08 | ||
| PCT/US2000/032760 WO2001042222A1 (en) | 1999-12-08 | 2000-12-01 | Polymorphic crystalline forms of celecoxib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516394A JP2003516394A (ja) | 2003-05-13 |
| JP2003516394A5 true JP2003516394A5 (https=) | 2008-01-24 |
Family
ID=46125623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001543523A Withdrawn JP2003516394A (ja) | 1999-12-08 | 2000-12-01 | セレコキシブの多型結晶形態 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7476744B2 (https=) |
| EP (2) | EP1150960B1 (https=) |
| JP (1) | JP2003516394A (https=) |
| AT (1) | ATE288897T1 (https=) |
| AU (1) | AU750978B2 (https=) |
| BR (1) | BR0008088A (https=) |
| CA (1) | CA2362675A1 (https=) |
| CY (1) | CY1106307T1 (https=) |
| CZ (1) | CZ20013210A3 (https=) |
| DE (1) | DE60018040T2 (https=) |
| DK (1) | DK1150960T3 (https=) |
| DZ (1) | DZ3140A1 (https=) |
| EA (1) | EA003464B1 (https=) |
| EE (1) | EE200100419A (https=) |
| GE (1) | GEP20043180B (https=) |
| HR (1) | HRP20010589A2 (https=) |
| IL (1) | IL144799A (https=) |
| IS (1) | IS6042A (https=) |
| MX (1) | MXPA01008161A (https=) |
| NO (1) | NO321062B1 (https=) |
| NZ (1) | NZ514059A (https=) |
| PL (1) | PL349224A1 (https=) |
| SI (1) | SI1150960T1 (https=) |
| SK (1) | SK11522001A3 (https=) |
| UA (1) | UA74539C2 (https=) |
| WO (1) | WO2001042222A1 (https=) |
| ZA (1) | ZA200207445B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200001872A2 (tr) | 2000-06-26 | 2002-01-21 | Fako �La�Lari A.� | 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine ilişkin yöntem. |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| WO2004078163A2 (en) * | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| CA2477923C (en) | 2002-03-01 | 2021-02-23 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| AU2002251329A1 (en) * | 2002-04-25 | 2003-11-10 | Generics (Uk) Limited | Novel crystalline forms of celecoxib and other compounds |
| WO2003091221A1 (en) * | 2002-04-25 | 2003-11-06 | Generics [Uk] Limited | Celecoxib forms |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| ATE550022T1 (de) | 2003-02-28 | 2012-04-15 | Mcneil Ppc Inc | Pharmazeutische mischkristalle von celecoxib- nicotinamid |
| WO2005014546A1 (en) * | 2003-08-08 | 2005-02-17 | Hetero Drugs Limited | Novel crystalline forms of celecoxib |
| CA2574326A1 (en) * | 2004-07-22 | 2006-05-18 | Pliva-Istrazivanje I Razvoj D.O.O. | Novel form of celecoxib |
| WO2006056770A1 (en) | 2004-11-23 | 2006-06-01 | Pliva Hrvatska D.O.O. | Extended release pharmaceutical composition of celecoxib |
| EP1846377A2 (en) * | 2005-01-31 | 2007-10-24 | Pharmacia & Upjohn Company LLC | Form iv crystalline celecoxib |
| PE20100241A1 (es) | 2005-09-19 | 2010-04-16 | Emisphere Tech Inc | Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico |
| CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
| CN104447716A (zh) | 2007-05-09 | 2015-03-25 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| EP3683218B1 (en) | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| MX365732B (es) | 2007-12-07 | 2019-06-12 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| US20110159050A1 (en) * | 2008-07-11 | 2011-06-30 | Basf Se | Amphiphilic proteins as morphology modifiers |
| AR073709A1 (es) * | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
| WO2011055233A2 (en) | 2009-11-03 | 2011-05-12 | Actavis Group Ptc Ehf | Improved process for preparing celecoxib polymorph |
| US20110213159A1 (en) * | 2010-03-01 | 2011-09-01 | Vamsee Krishna Muppidi | Process for preparation of celecoxib crystalline form |
| JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与 |
| EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CN103193677A (zh) * | 2013-03-22 | 2013-07-10 | 南开大学 | 美索巴莫磷酸二钠盐的多晶型及其制备方法 |
| CN103130684A (zh) * | 2013-03-22 | 2013-06-05 | 南开大学 | 美索巴莫磷酸二钾盐的多晶型及其制备方法 |
| AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
| CN107408147A (zh) * | 2015-01-13 | 2017-11-28 | 奥托泰里克有限责任公司 | 用于个体化药物治疗的方法 |
| JP6499948B2 (ja) * | 2015-09-09 | 2019-04-10 | 株式会社トクヤマ | セレコキシブｉｉ型結晶の製造方法 |
| JP7108681B2 (ja) | 2017-08-11 | 2022-07-28 | アモーレパシフィック コーポレーション | （ｒ）‐ｎ‐［１‐（３，５‐ジフルオロ‐４‐メタンスルホニルアミノ‐フェニル）‐エチル］‐３‐（２‐プロピル‐６‐トリフルオロメチル‐ピリジン‐３‐イル）‐アクリルアミドを含む医薬組成物 |
| KR102518632B1 (ko) | 2018-04-18 | 2023-04-06 | (주)아모레퍼시픽 | (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물 |
| CN113005176A (zh) * | 2019-12-20 | 2021-06-22 | 深圳市帝迈生物技术有限公司 | 稳定剂、凝血酶原时间检测试剂及其制备方法、试剂盒 |
| CN119656108B (zh) * | 2025-02-21 | 2025-05-30 | 墨格微流科技(汕头)有限公司 | 一种米诺地尔纳米晶混悬液及其制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| WO1993025190A1 (en) | 1992-06-10 | 1993-12-23 | Eastman Kodak Company | Surface modified nsaid nanoparticles |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| ES2141916T3 (es) * | 1993-11-30 | 2000-04-01 | Searle & Co | Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion. |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5981576A (en) | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
| WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| EP0863134A1 (en) | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
| CA2328992A1 (en) | 1998-04-27 | 1999-11-04 | Northwest Hospital | Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
| EP1144383A1 (en) * | 1999-01-14 | 2001-10-17 | Merck Frosst Canada & Co. | Synthesis of 4-[(5-substituted or unsubstituted phenyl)-3-substituted-1h-pyrazol-1-yl]benzenesulfonamides |
| AU4308300A (en) * | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| SK12682001A3 (sk) * | 1999-12-08 | 2002-07-02 | Pharmacia Corporation, Corporate Patent Department | Celecoxib v tuhej forme so zvýšenou biologickou dostupnosťou |
| TR200001872A2 (tr) * | 2000-06-26 | 2002-01-21 | Fako �La�Lari A.� | 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine ilişkin yöntem. |
-
2000
- 2000-01-12 UA UA2001085658A patent/UA74539C2/uk unknown
- 2000-12-01 GE GEAP20006102A patent/GEP20043180B/en unknown
- 2000-12-01 SI SI200030663T patent/SI1150960T1/xx unknown
- 2000-12-01 NZ NZ514059A patent/NZ514059A/xx unknown
- 2000-12-01 MX MXPA01008161A patent/MXPA01008161A/es not_active IP Right Cessation
- 2000-12-01 EP EP00983865A patent/EP1150960B1/en not_active Expired - Lifetime
- 2000-12-01 DK DK00983865T patent/DK1150960T3/da active
- 2000-12-01 PL PL00349224A patent/PL349224A1/xx not_active Application Discontinuation
- 2000-12-01 WO PCT/US2000/032760 patent/WO2001042222A1/en not_active Ceased
- 2000-12-01 EP EP05002575A patent/EP1528058A1/en not_active Withdrawn
- 2000-12-01 EE EEP200100419A patent/EE200100419A/xx unknown
- 2000-12-01 AU AU20571/01A patent/AU750978B2/en not_active Ceased
- 2000-12-01 EA EA200100874A patent/EA003464B1/ru not_active IP Right Cessation
- 2000-12-01 IL IL144799A patent/IL144799A/en unknown
- 2000-12-01 US US09/728,040 patent/US7476744B2/en not_active Expired - Fee Related
- 2000-12-01 JP JP2001543523A patent/JP2003516394A/ja not_active Withdrawn
- 2000-12-01 HR HR20010589A patent/HRP20010589A2/hr not_active Application Discontinuation
- 2000-12-01 CA CA002362675A patent/CA2362675A1/en not_active Abandoned
- 2000-12-01 DE DE60018040T patent/DE60018040T2/de not_active Expired - Fee Related
- 2000-12-01 AT AT00983865T patent/ATE288897T1/de not_active IP Right Cessation
- 2000-12-01 DZ DZ003140A patent/DZ3140A1/xx active
- 2000-12-01 BR BR0008088-8A patent/BR0008088A/pt not_active Application Discontinuation
- 2000-12-01 SK SK1152-2001A patent/SK11522001A3/sk unknown
- 2000-12-06 CZ CZ20013210A patent/CZ20013210A3/cs unknown
-
2001
- 2001-08-08 IS IS6042A patent/IS6042A/is unknown
- 2001-08-08 NO NO20013868A patent/NO321062B1/no unknown
-
2002
- 2002-09-17 ZA ZA200207445A patent/ZA200207445B/en unknown
-
2005
- 2005-04-21 CY CY20051100501T patent/CY1106307T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003516394A5 (https=) | ||
| CA2537092A1 (en) | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| CA2360557A1 (en) | Biodegradable and thermosensitive polyphosphazenes and their preparation method | |
| JP2007532560A5 (https=) | ||
| CA2514169A1 (en) | Process for obtaining 17.alpha.-acetoxy-11.beta.(4-n,n-dimethylaminophenyl-19-norpregna-4,9-diene-3,20-dione | |
| CA2354880C (en) | Method for the preparation of citalopram | |
| CA2056067A1 (en) | A physical form of n-¬4-¬5-(cyclopentyloxcarbony)-amino-1-methylindol-3-yl-methyi|-3-methoxybenzoy1|-2-methyibezenesulphonanide, processes for its preparation and compositions containing it | |
| AU2001264804A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| WO2001092230A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JP2003514859A5 (https=) | ||
| ZA200207675B (en) | Novel crystal form of pyrrolidylthiocarbapenem derivative. | |
| WO2001090137A3 (de) | NEUE FESTKÖRPERFORMEN DES MESOPROGESTINS 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ON | |
| EP1903041A3 (en) | Polymorphic and other crystalline forms of cis-FTC | |
| JP6091881B2 (ja) | ＢａＴｉ２Ｏ５系複合酸化物の製造方法 | |
| JP2004530660A5 (https=) | ||
| TWI242538B (en) | Method for manufacturing crystalline powder of a lithium and vanadium oxide | |
| RU2003106718A (ru) | Способ получения мелкодисперсного порошка титана | |
| JP2002316865A5 (https=) | ||
| JP2002020525A5 (https=) | ||
| CN101747302B (zh) | 一种多取代苯并呋喃化合物的合成方法 | |
| JP2005501857A5 (https=) | ||
| JPH04244067A (ja) | ヘキサヒドロピリダジン−１，２−ジカルボキシ誘導体の製造法 | |
| JP2003512370A5 (https=) | ||
| JP2002506064A5 (https=) | ||
| JPS542912A (en) | Sintered hard alloy |